本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2020/12/231 分钟阅读
Endo Pharmaceuticals, Inc.; Withdrawal of Approval of a New Drug Application for OPANA (Oxymorphone Hydrochloride) Extended-Release Tablets
本地自动翻译 · 来源原始语言
摘要
The Food and Drug Administration (FDA) is withdrawing approval of the new drug application (NDA) for OPANA (oxymorphone hydrochloride) extended-release (ER) tablets (NDA 201655), held by Endo Pharmaceuticals, Inc., 1400 Atwater Dr., Malvern, PA 19355 (Endo). Endo requested that the approval of this application be withdrawn and has waived its opportunity for a hearing.
来源原始语言: Federal Register — Food and Drug Administration打开原始公告 →